Bioventus (NYSE:BVS) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Bioventus (NYSE:BVS - Free Report) in a report released on Monday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $12.00 price target on the stock.

A number of other brokerages also recently issued reports on BVS. Craig Hallum set a $15.00 price objective on Bioventus and gave the company a "buy" rating in a research note on Wednesday, May 7th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 price target on shares of Bioventus in a research note on Monday, March 17th.

Bioventus Trading Up 1.0%

Shares of NYSE:BVS traded up $0.07 during midday trading on Monday, reaching $7.39. The company's stock had a trading volume of 296,552 shares, compared to its average volume of 428,811. The firm has a market capitalization of $607.04 million, a price-to-earnings ratio of -12.11 and a beta of 0.84. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The firm has a 50 day moving average price of $6.70 and a two-hundred day moving average price of $8.55. Bioventus has a fifty-two week low of $5.87 and a fifty-two week high of $14.38.

Insiders Place Their Bets

In related news, CFO Mark Leonard Singleton sold 3,875 shares of the company's stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $7.57, for a total transaction of $29,333.75. Following the transaction, the chief financial officer directly owned 141,088 shares of the company's stock, valued at approximately $1,068,036.16. This represents a 2.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 33.00% of the company's stock.

Institutional Trading of Bioventus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BVS. Tower Research Capital LLC TRC increased its holdings in Bioventus by 106.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock worth $36,000 after purchasing an additional 1,786 shares in the last quarter. GAMMA Investing LLC increased its holdings in Bioventus by 3,228.7% during the 1st quarter. GAMMA Investing LLC now owns 5,792 shares of the company's stock worth $53,000 after purchasing an additional 5,618 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Bioventus by 23,761.5% during the 1st quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company's stock worth $57,000 after purchasing an additional 6,178 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Bioventus during the 4th quarter worth approximately $75,000. Finally, Quantbot Technologies LP bought a new stake in Bioventus during the 4th quarter worth approximately $103,000. 62.94% of the stock is owned by institutional investors.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.